Ryan E Robinson, Elena Mitsi, Elissavet Nikolaou, Sherin Pojar, Tao Chen, Jesús Reiné, Tinashe K Nyazika, James Court, Kelly Davies, Madlen Farrar, Patricia Gonzalez-Dias, Josh Hamilton, Helen Hill, Lisa Hitchens, Ashleigh Howard, Angela Hyder-Wright, Maia Lesosky, Konstantinos Liatsikos, Agnes Matope, Daniella McLenaghan, Christopher Myerscough, Annabel Murphy, Carla Solórzano, Duolao Wang, Hassan Burhan, Manish Gautam, Elizabeth Begier, Christian Theilacker, Rohini Beavon, Annaliesa S Anderson, Bradford D Gessner, Stephen B Gordon, Andrea M Collins, Daniela M Ferreira
RATIONALE: Streptococcus pneumoniae serotype 3 (SPN3) is a cause of invasive pneumococcal disease and associated with low carriage rates. Following the introduction of pediatric 13-valent pneumococcal conjugate vaccine (PCV13) programmes, SPN3 declines are less than other vaccine serotypes and incidence has increased in some populations coincident with a shift in predominant circulating SPN3 clade, from I to II. A human challenge model provides an effective means for assessing the impact of PCV13 on SPN3 in the upper airway...
July 8, 2022: American Journal of Respiratory and Critical Care Medicine